Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer
Heikki Joensuu(Orion Corporation (Finland)), Henrik Lindman(Uppsala University), Jouni Junnila, Paula Poikonen‐Saksela(Turku University Hospital), Arja Jukkola‐Vuorinen(University of Oulu), Päivi Auvinen(University of Eastern Finland), Minna Tanner(Tampere University Hospital), Paul Nyandoto(Päijät-Hämeen Keskussairaala), Outi Lahdenperä(Turku University Hospital), Sanna Kosonen(Kotka Maritime Research Centre), Johan Ahlgren(Uppsala University), Vesa Kataja(Kuopio University Hospital), Riikka Huovinen(Turku University Hospital), Greger Nilsson(Turku University Hospital), Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono(Helsinki University Hospital), Kenneth Villman(Örebro University Hospital), R. Kokko
Cited by 95
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k